CT Screening for Lung Cancer

An international, two-day intensive course for practicing clinicians on CT screening for lung cancer will start Friday December 5, 2014. Learn more

Thoracic Surgery Research

The Department of Thoracic Surgery is committed to advancing the diagnosis and treatment of congenital and acquired diseases of the lungs, esophagus, mediastinum, and chest wall. In addition to the leading-edge treatments we currently provide—including video-assisted thoracoscopic surgery (VATS) lobectomy and robotic surgery—we are striving to further improve patient care through basic research and clinical trials in areas such as the following:  

  • Lung Cancer: Mount Sinai is conducting an array of research studies and clinical trials to improve upon both the diagnosis and treatment of lung cancer. Areas of focus include a cessation study and examining biological indicators of aggressive early-stage lung cancer and immune-fighting cells in the lung.

  • Mesothelioma: The Thoracic Surgery Translational Laboratory is working to identify the key proteins and important pathways involved in this form of cancer. Mount Sinai investigators are developing novel tests to determine which mesothelioma tumors have abnormal transcription factor activity, and designing drug therapies intended to inhibit these factors.

  • Libby Epidemiology Research Project: Mount Sinai has received a $4.8 million RO1 grant to examine the health impact of asbestos exposure, funded by the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Researchers are investing the disease pathology in the town of Libby, MT, with the goals of assessing risks of exposure to asbestos during childhood; examining the relationships between autoimmune disorders, autoimmune antibody abnormalities, and CT-scan evidence of related scarring lung disease; and recommending environmental cleanup efforts.

  • Personalized and Targeted Therapy: Research at the Thoracic Surgery Translational Laboratory is focused on developing personalized therapies for a range of thoracic malignancies. Current efforts include work to identify and design novel small molecule inhibitors for the treatment of drug resistant cancers.

Contact Us

General inquiries:
212-241-9466

Residency and Fellowship inquiries:
Andrew Kaufman, MD
212-241-8842
Send email